Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Xue-Ning Yang, Yi-Long Wu, Li-Xu Yan, Xu-Chao Zhang, Hai-Yan Tu, Si-Pei Wu, Y. Li, Zhong-Yi Dong, Jian Su, Jin-Ji Yang, Zhi Xie, Si-Yang Liu, Qing Zhou, Wen-Zhao Zhong, Hong-Hong Yan
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 125
EGFR-mutated or ALK-rearranged non-small cell lung cancer (NSCLC) often showed unfavorable clinical benefit to checkpoint inhibitors (CPIs). However, few reports exist with integrated analysis, to interpret the underlying mechanism of poor response t
Publikováno v:
Lung Cancer
OBJECTIVES: Cripto-1 (CR-1) plays a critical role in the activation of SMAD, SRC, and epithelial-to-mesenchymal transition (EMT) pathways and has been shown to be prognostic in several cancer types. In addition, we showed that CR-1 renders EGFR-mutat
Autor:
Tomoko Dai, Masayuki Noguchi, Akiko Sakata, Toshihiro Shiozawa, Masao Ono, Ryan Edbert Husni, Hirotsugu Kohrogi, Shinji Iyama, Hitomi Kawai-Nakahara
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 102
Objectives With the aim of searching for novel oncofetal tumor biomarkers of lung adenocarcinoma other than carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP), we developed a strategy involving monoclonal antibodies generated from embryonic t
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 97
PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characte
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 88(1)
Programmed cell death-1 (PD-1)/programmed cell death-ligand-1 (PD-L1) pathway-targeted immunotherapy has beneficial therapeutic effects in pulmonary squamous cell carcinoma (SqCC) patients. However, the expression patterns of PD-1 and PD-1 ligands (P
Autor:
Hironori Haga, Tatsuaki Tsuruyama, Masashi Kobayashi, Motoki Sato, Hiroshi Date, Akihiko Yoshizawa, Shinji Sumiyoshi, Makoto Sonobe, Masakazu Fujimoto
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 84(3)
a b s t r a c t Objectives: The characteristics of non-terminal respiratory unit (TRU) type lung adenocarcinoma are still unclear. The aim of the present study was to characterize non-TRU type lung adenocarcinoma. Materials and methods: We analyzed t
Autor:
Yu Jin Kim, Do Hyeong Lee, Mi Jeong Kwon, Sanghui Park, Jinwon Seo, Yoon-La Choi, Jun Young Choi, Young Kee Shin, Joungho Han, Tae-Eun Kim, Mi Jung Kwon
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 81(1)
The overexpression of tetraspanin CD151 - a transmembrane protein that promotes tumor invasion and metastasis - is associated with poor prognosis in various cancers. However, its clinical significance in non-small cell lung cancers (NSCLCs) has not b
Autor:
Shilpi Arora, Irene Cherni, Guy M. Raz, Carlos D. Lorenzo, Galen Hostetter, Kristi Allen, Chris Kingsley, Glen J. Weiss, Shravan Sridhar, Aprill Watanabe, David K. Edwards
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 76(2)
Introduction The Hedgehog Signaling Pathway (HHSP) has been implicated in the development of multiple cancers. HHSP activation may primarily be hedgehog ligand-dependent in non-small cell lung cancer (NSCLC); while a subset may be ligand-independent.
Autor:
Hidetaka Uramoto, Makoto Nakagawa, Hidehiko Shimokawa, Takamitsu Onitsuka, Takeshi Hanagiri, Teruo Iwata, Kenji Ono
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 72(3)
Background Not all patients with lung cancer require postoperative adjuvant chemotherapy after a complete resection. However, no useful markers for either selecting appropriate candidates or for predicting clinical recurrence exist. Methods Tumor spe
Autor:
Seung Soo Sheen, Jin-Hyuk Choi, Joo Hun Park, Hye Lim Lee, Young Sun Kim, Woo Young Chung, Kyi Beum Lee, Kyung Joo Park, Kwang Joo Park, Young Bae Kim, Ho Choi, Sung Chul Hwang, Keu Sung Lee, Sungsoo Lee
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 66(3)
Purpose: We evaluated the clinical significance of angiopoietins and vascular endothelial growth factor (VEGF) in patients with resected early stage lung cancer. Patients and methods: The study enrolled 101 patients with completely resected non-small